

Classification	Classified Policy	Shared Growth Policy of SK Biopharmaceuticals	Date of Revision	2023.10
Page	③		Revision No.	0.2

1. Overview

Vendors of SK Biopharmaceuticals can be divided mainly into raw material suppliers, contract manufacturing organizations (CMOs), and suppliers for the materials necessary for overall operation. With no owned production facility, SK Biopharmaceuticals carries out all the manufacturing-related operations in the commercialization phase of new drugs after marketing approval through close cooperation with CMOs, ranging from procurement of raw materials, product production, quality control to process improvement. SK Biopharmaceuticals is expanding collaboration with not only CMOs but also material procurement vendors and has introduced and faithfully implemented four action policies. (fair and transparent selection of vendors through a procurement bidding system, fostering a fair and transparent trading environment, training support for vendors, and discovery of collaborative tasks)

2. Action Policies

(1) Fair and transparent selection of vendors through a procurement bidding system

SK Biopharmaceuticals issues electronic tenders fairly and transparently using the procurement bidding system ('epro').

(2) Fostering a fair and transparent trading environment

SK Biopharmaceuticals is dedicated to fostering a fair and transparent trading environment in accordance with our procurement policies while strengthening internal/external inspections by the Compliance Team.

(3) Training support for vendors

SK Biopharmaceuticals provides our vendors with various training opportunities aiming to create and nurture a community for co-prosperity.

(4) Discovery of collaborative tasks

SK Biopharmaceuticals has worked with critical vendors to discover and monetize collaborative tasks as a part of our commitment to shared growth.

3. Shared Growth Roadmap

SK Biopharmaceuticals has established a roadmap to achieve shared growth with our vendors by the year 2030 and is faithfully committed to implementing it.

Classification	Classified Policy	Shared Growth Policy of SK Biopharmaceuticals	Date of Revision	2023.10
Page	③		Revision No.	0.2

(1) 2024 : Establishment of Shared Growth Programs and Collaboration

- Enhancing vendors' competitiveness through programs such as PSCI audit cost support for key managed companies
- Expansion of education programs for vendors

(2) 2027 : Cultivating a Fair and Transparent Trading Culture, Expanding Shared Growth Programs, and Strengthening Collaboration

- Strengthening internal and external compliance activities to establish a fair and transparent trading culture
- Expanding Shared Growth programs for non-majored partners
- Developing future pipelines with key vendors and collaborating to promote shared growth

(3) 2030 : Expansion of Joint Technology Development and Shared Growth Funds to Approximately 0.2% of Revenue

- Supporting an increase in revenue for vendors through joint technology development
- Expanding the scale of education, welfare, and management support